BioPharma« Terug naar discussie overzicht

1. [verwijderd] 3 mei 2008 10:17

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   WEIFANG, China, May 1 /Xinhua-PRNewswire-FirstCall/ -- Shengtai
   Pharmaceutical, Inc. (OTC Bulletin Board: SGTI.OB) ("Shengtai
   Pharmaceutical" or "the Company"), a leading manufacturer and distributor
   of high-quality, pharmaceutical grade glucose products in China and glucose
   and starch products that serve as raw materials for food, beverage and
   industrial production today announced the appointment of Ms. Melody Shi as
   its Chief Financial Officer effective April 30, 2008. Ms. Shi replaces Mr.
   Yizhao Zhang, who resigned effective April 30, 2008 for personal reasons.
   
   Ms. Shi has 10 years' working experience in the fields of financial
   control, auditing and business analysis in both China and the U.S. Since
   2005, she has acted as audit manager for Kabani & Co. Inc., where she led
   the China practice which was responsible for auditing the financial results
   of more than 50 PRC companies that are public in the U.S. and reviewing
   related filings with the U.S. Securities and Exchange Commission. Prior to
   2005, Ms. Shi served as controller at Aroa Marketing, channel program
   manager at Sun Microsystems and financial analyst at Hewlett Packard China.
   Ms. Shi holds an MBA from the University of California, Irvine and
   Bachelor's degrees in Computer Science and International Trade and Business
   from Beijing Polytechnic University. Ms. Shi is a Certified Public
   Accountant and is fluent in English and Mandarin.
   
   "I am very pleased to join Shengtai during this time of rapid growth
   and strong performance," commented Ms. Shi. "I look forward to adding my
   experience and expertise to an already impressive management team."
   
   "We welcome Ms. Shi to our management team, and believe her expertise
   in financial reporting for U.S. listed Chinese companies will enhance our
   disclosure and improve our communication with our investors," said Mr.
   Qingtai Liu, Shengtai Pharmaceutical's Chairman and CEO.
   
2. [verwijderd] 13 mei 2008 09:46

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   $3,50....vrijdag cijfers. kan leuk worden
3. Striker_ 13 mei 2008 10:47

   auteur info

   •    Striker_

     Lid sinds: 09 mrt 2004

     Laatste bezoek: 27 jul 2024

   •    Aanbevelingen

     Ontvangen: 45

     Gegeven: 15

   •    Aantal posts: 2.834

   Ben benieuwd
4. [verwijderd] 13 mei 2008 13:52

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   ik ook....heb leuke informatie gekregen van onze dame die nu de cfo functie heeft....
   
   Our goal is to apply to NASDAQ or AMEX in the second half of the year. By the way, our new factory is going through testing phase now and will be put into operation soon, and international leaders such as Cargill has visiting us and negotiating M&A. Global hunter has issued an analysis report last month saying that target price is about $5.90 in 12months. Roth will issue their report by early next month. In all signs, I am confident that your investment is a good choice.
   vooral het Cargill stukje is interessante info.
   
   Cargill is an international provider of food, agricultural and risk management products and services. We are committed to using our knowledge and experience to collaborate with customers to help them succeed.
5. [verwijderd] 13 mei 2008 13:56

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   als die amex eraan komt kan dit van een p/e van 5,5 naar een p/e van 20 met hun groei en business waarin ze aktief zijn...kortom een aantal keren je inleg....ik blijf tot op zn minst in dit aandeel totdat de amex/nasdaq notering een feit is.
6. Striker_ 13 mei 2008 14:00

   auteur info

   •    Striker_

     Lid sinds: 09 mrt 2004

     Laatste bezoek: 27 jul 2024

   •    Aanbevelingen

     Ontvangen: 45

     Gegeven: 15

   •    Aantal posts: 2.834

   cool, mijn pakket maar eens uitbreiden dan.
   gigm ook weer lekkere cijfers, die houd ik nog minimaal 1,5-2 jaar vast.
7. Striker_ 13 mei 2008 22:08

   auteur info

   •    Striker_

     Lid sinds: 09 mrt 2004

     Laatste bezoek: 27 jul 2024

   •    Aanbevelingen

     Ontvangen: 45

     Gegeven: 15

   •    Aantal posts: 2.834

   zo vandaag uitgebreid naar 2k, nu maar laten verstoffen tot de de koers echt losbarst.
8. [verwijderd] 14 mei 2008 08:57

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   ik probeer vandaag ook nog enkele stukken binnen te harken....
   
   Ik vind dat Cargill stukje heel erg interessant dat MS shi vermeld heeft in haar mail.....
   
   Doe eens googlen op cargill merge en/of Aquisition...dan krijg je me toch een waslijst van overgenomen voedingsbedrijven over de hele wereld.
   
   en het mailtje lezende is cargill dus bij shengtai op bezoek geweest om M&A te bespreken.... M&A is merger and aquisition naar mijn weten.
   
   cargill interesse in dit bedrijf??
   
   
9. [verwijderd] 14 mei 2008 16:32

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   uit het research report van Jodie wehner":
   
   M&A opportunities. The company acknowledged that it has ongoing conversations with two major
   domestic competitors and does not exclude the fact that they might merge with them or buy them. We
   believe that we are looking for a potential M&A opportunity in 2008-2009. If this succeeds, such an
   acquisition could potentially make Shengtai the largest pharmaceutical glucose manufacturer in Asia,
   contrasting with Cargill on the western globe. We believe that such an acquisition could solidify
   Shengtai’s market position, increase its bargaining power for both supply and end product prices,
   thereby greatly supplementing its organic growth.
   
   Daar noemen ze cargill ook al maar dan als een concurrent...en dat ze in 2008-2009 een overname gaan doen...
   
   if you cant beat them..............
   $10,- per aandeel mogen ze de stukken hebben;-)
   
   
10. Striker_ 14 mei 2008 17:07

    auteur info

    •    Striker_

      Lid sinds: 09 mrt 2004

      Laatste bezoek: 27 jul 2024

    •    Aanbevelingen

      Ontvangen: 45

      Gegeven: 15

    •    Aantal posts: 2.834

    Dat is mijn koersdoel voor eind 2009.
    Als een partij als Cargill dat er nu al voor neer wil leggen prima ;)
11. [verwijderd] 16 mei 2008 09:27

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Q3
    
    Sales revenue for the three months ended March 31, 2008 was $20,701,557, an increase of $8,138,489, or 64.78% compared with the corresponding period in 2007. The increased sales revenues were principally due to our cornstarch production, higher product prices, and the diversification of product lines and the expansion of sales of higher-value products.
    
    Costs of goods sold for the three months ended March 31, 2008 was $16,220,665, an increase of $6,923,663, or 74.47% compared with the corresponding period in 2007. The increase in cost of goods sold is primarily resulted from the increase in sales of our products and the increase of the raw material.
    
    Gross profit for the three months ended March31, 2008 was $4,480,912, an increase of $1,214,826, or 37.20% compared with the corresponding period in 2007. The increase in gross profit was principally attributable to the economies of scale resulting from the expansion of our production output and enhanced operating efficiencies. At the same time, we were able to pass on raw material cost increases to our customers on some product lines.
    
    Gross profit margin for the three months ended March 31, 2008 was 21.65%, a decrease from 26.00% for the same period in 2007. This four percentage points decrease of overall gross profit margin was principally due to the increase price of raw material, and our increased sales of cornstarch, a product with lower profit margin.
    
    Selling, General and Administrative expenses for the three months ended March 31, 2008 was $1,603,932, an increase of $544,353, or 51.37% compared with the corresponding period in 2007. The increase in our Selling, General and Administrative expenses was the result of stock option issued in Janunary 2008, the expansion of our production output and domestic sales network. Larger quantity of cornstarch also called for higher shipping costs.
    
    Net income for the three months ended March 31, 2008 was $1,887,153, an increase of 94,060, or 5.25% compared with the corresponding period in 2007. The increase of net income was due to Sales increase.
    
    Boven verwachting van analisten ,netto income gedrukt door veel extra kosten gemaakt mbt de nieuw te openen facility.
    
    kortom weer mooie cijfertjes....
    
    kijk uit naar de Conference call vanmiddag.
    
    
12. [verwijderd] 16 mei 2008 09:36

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    en dan te zien dat SHenghuo nu op een p/e van 26 staat en shengtai met hun vele grotere groei op 5,6
    
    enige verschil? Amex notering...hoop dan ook dat Ms SHi vanmiddag de info vrijgeeft die ze mij heeft gegeven.
13. [verwijderd] 17 juni 2008 15:01

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Shengtai Pharmaceutical has nearly finished the construction of the new glucose production complex with expected annual production capacity of 120,000 metric tons. The new facility has been equipped with state-of-the-art, high-tech operational machines and since May 2008, the Company successfully launched trial production of glucose products. This facility combined with the Company's existing glucose facility will provide total production capacity of 210,000 metric tons of glucose per year. Once the plant is fully operational, Shengtai's glucose quality will be able to match that produced in the rest of the world.
    
    The trial production and quality tests are categorized by products -- food and beverage grade glucose, monohydrate glucose and anhydrous glucose. The Company has adopted a series of production and quality control tests to measure the results of the trial production stage, including pH scale, specific gravity, DE scale, temperature and luminousness.
    
    The trial production results for food and beverage grade glucose were the first to pass the tests due to their relatively lower testing standards. Monohydrate glucose and anhydrous glucose products are still in trial production and undergoing quality control tests due to their higher testing standards. The Company still needs to install supplemental equipment to complete their tests.
    
    "We expect the monohydrate glucose and anhydrous glucose trial production and quality tests will be able to meet all production requirements and testing standards by the end of June 2008," said Chairman and CEO, Mr. Qingtai Liu, "We will start our official production as soon as we successfully complete trial production and related tests, and expect the new glucose facility to reach its full production capacity in about one and a half years. More cornstarch produced from our new cornstarch production facility will be utilized internally to produce glucose out of our new glucose facility, which should improve our overall gross profit margin. The additional contribution from our new glucose plant should further satisfy the robust demand for glucose products, especially for pharmaceutical grade glucose products."